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ABSTRACT
The increase in Gram-negative broad-spectrum antibiotic resistance is worrisome, particularly as there
are few, if any, ‘‘pipeline’’ antimicrobial agents possessing suitable activity against Pseudomonas spp. or
Acinetobacter spp. The increase in resistance will be further enhanced by the acquisition of metallo-
b-lactamase (MBL) genes that can potentially confer broad-spectrum b-lactam resistance. These genes
encode enzymes that can hydrolyse all classes of b-lactams and the activity of which cannot be
neutralised by b-lactamase inhibitors. MBL genes are often associated with aminoglycoside resistant
genes and thus bacteria that possess MBL genes are often co-resistant to aminoglycosides, further
compromising therapeutic regimes. Both types of genes can be found as gene cassettes carried by
integrons that in turn are embedded within transposons providing a highly ambulatory genetic element.
The dissemination of MBL genes is typiﬁed by the spread of blaVIM-2, believed to originate from a
Portuguese patient in 1995, and is now present in over 20 counties. The increase in international travel is
likely to be a contributory factor for the ascendancy of mobile MBL genes as much as the mobility among
individual bacteria. Fitness, acquisition and host dependency are key areas that need to be addressed to
enhance our understanding of how antibiotic resistance spreads. There is also a pressing need for new,
and hopefully novel, compounds active against pan-resistant Gram-negative bacteria – a growing
problem that needs to be addressed by both government and industry.
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INTRODUCTION
The frequency of antibiotic resistance in Gram-
negative bacteria is likely to continue to rise and,
while new drugs such as linezolid and daptomy-
cin can be employed against Gram-positive infec-
tions, new anti-Gram-negative drugs are
conspicuous by their absence. Gram-negative
resistance has probably now eclipsed Gram-pos-
itive resistance and has prompted similar calls for
the implementation of infection control measures
to negate the dissemination of these organisms
[1]. A recent survey of Gram-negative resistance
from North America showed that Pseudomonas
aeruginosa has become increasingly resistant, with
cefepime, imipenem and meropenem still main-
taining good activity [2]. Global SENTRY data
broadly support the previous study, in that
P. aeruginosa showed moderate levels of resistance
to cefepime (10%), imipenem (12%) and merope-
nem (10%) [3]. A longitudinal survey from the
UK did not show an increase in P. aeruginosa
resistance but did highlight a worrying and
dramatic increase in resistance of Enterobacteria-
ceae and Acinetobacter spp. to cephalosporins,
quinolones and aminoglycosides. The recent
increase in Enterobacteriaceae acquiring the ‘new-
er’ extended-spectrum b-lactamase genes, e.g.,
blaCTX-M, blaOXA and blaCMY, while concurrently
becoming resistant to quinolone antibiotics, is
becoming a commonplace scenario [4]. While
such studies have often been reported from
‘developed countries’, a similar trend in resist-
ance is found elsewhere. A longitudinal study
from India showed a dramatic increase in the
resistance of P. aeruginosa to most anti-infectives,
particularly ceftazidime (52–94%). The recent
multinational neonatal infection survey by Zaidi
et al. further highlights the increase in infections
with and resistance in Gram-negative bacteria [5].
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Treatment regimens for such bacteria are
limited and may involve aminoglycosides
and ⁄ or broader-spectrum b-lactams such as
carbapenems. Resistance to carbapenems in
Gram-negative bacteria may take on many
guises, including permeability barriers and ⁄ or
hydrolysis by b-lactamases. Recent studies have
shown that outer-membrane mutations in En-
terobacteriaceae and Acinetobacter spp. can sin-
gularly mediate low-level resistance to imipenem
[6]. Enzymes mediating resistance to carbapen-
ems can be divided into serine b-lactamases and
those possessing a metal ion(s) at their active
site. Serine carbapenemases include NmcA, Sme-
type IMI-1, KPC type, GES type and OXA type
[7–16]. Those that possess metal at their active
site are termed metallo-b-lactamases (MBLs) and
come from a disparate group of bacteria; these
are classiﬁed as group 3 or class B [17–19]. There
exists a plethora of reasons why MBLs are likely
to displace serine carbapenemases as the key
group of enzymes capable of hydrolysing carb-
apenems. This brief appraisal, while unavoidably
parsimonious, will give an insight into the
contribution of MBLs to Gram-negative resist-
ance and why there is a growing concern about
the lack of appropriate therapeutic regimens.
GENETIC LOCATION OF MBL GENES
As with any molecular class of b-lactamase, MBLs
can be broadly divided into those that are ‘mobile’
and those that are normally carried by the host
organism on the chromosome. Those that are
normally chromosomally encoded are usually
derived from organisms whose habitat is predom-
inantly environmental. Consequently, there is
some debate as to why this is the case, but the most
plausible explanation is that these enzymes per-
formanormal cellular function that is yet to be fully
elucidated. Irrespectively, these organisms are
seldom pathogenic and, with the arguable excep-
tion of Stenotrophomonas maltophilia and Bacillus
anthracis, rarely cause serious infections [20,21].
Most ‘mobile’ MBL genes are carried on various
genetic elements that aid their movement from one
genetic apparatus to another. Genes encoding IMP
and VIM types as well as GIM-1 are found as gene
cassettes in class 1 integrons [22–27], although IMP-
typeMBL genes are also found on class 3 integrons
[28,29]. Integrons are capable of procuring gene
cassettes via a site-speciﬁc recombination event
between two DNA sites, one in the integron and
one in the gene cassette. Integrons consist of three
regions: the 5¢-conserved region (5¢CS), the 3¢-
conserved region (3¢CS) and a variable region.
Frequently, other gene cassettes are also seques-
tered and inserted, themost notable example being
the aacA4 gene, which encodes kanamycin, neo-
mycin, amikacin and streptomycin resistance.
Thus, one integron can carry resistance to one or
more classes of antibiotic and, accordingly, either
aminoglycosides or b-lactams could, potentially,
select for the resistant element. However, the
genetic plasticity is further enhanced when the
mobility of integrons is facilitated by other genetic
elements such as plasmids and transposons [30]. In
2003, the ﬁrst account was published of an MBL
gene (blaIMP-13) and its integron being embedded in
a Tn5051-type transposon from an Italian P. aeru-
ginosa isolate [31]. Additional studies showed that
the elements containing blaIMP-13 and blaVIM-2 from
a P. aeruginosa strain from Poland were inserted in
an identical site. Moreover, the tnpR genes of the
transposon from both sites are identical, suggest-
ing that the transposon is responsible for dissem-
ination of the class 1 integron,which then procured
the different MBL genes [31].
While the majority of MBL genes are mobilised
by integrons ⁄ transposons, a minority appear to be
mobilised with mobile common regions (CRs)
that have also been associated with other mobile
elements called SXT regions. The gene encoding
SPM-1, which appears to be restricted to Brazil, is
associated with two different types of CR element
[32]. Further analysis of the Brazilian P. aeruginosa
isolates demonstrated that the upstream DNA
contained common regions or CR elements, in
this case CR4 [33]. Compared to integrons and
transposons, very little is known about CR ele-
ments, particularly how they facilitate the mobi-
lisation of resistance genes [34].
ACQUIRED MBLS IN
GRAM-NEGATIVE BACTERIA
Those MBL genes that can be described as mobile
include those encoding CﬁA (or CcrA), IMP, VIM,
SPM and GIM. The ﬁrst of these to be character-
ised was the gene for CﬁA, which is predomin-
antly associated with Bacteroides spp. [35]. The
enzyme has been well studied and has often been
utilised as a paradigm for mechanistic studies
[36,37,]. The CﬁA gene is often quiescent, and its
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expression is dependent on the implantation of
insertion elements such as IS942, IS1186 and
IS4351, thereby providing a hybrid promoter
and facilitating its expression [38–40].
The ﬁrst ‘mobile’ MBL to be characterised
outside Bacteroides spp. was IMP-1, with the dis-
covery of P. aeruginosa strain GN17203 in Japan in
1988 [15]. The isolate possessed an imipenem MIC
of 50 mg ⁄L, as well as resistance to extended-
spectrum cephalosporins, e.g., ceftazidime MIC of
> 400 mg ⁄L. The resistance allele was found on a
transferable conjugative plasmid that could be
readily mobilised to other Pseudomonas strains.
Three years later, an identical gene was found in
Serratia marcescens strain Tn9106 isolated from a
urinary tract infection at Aichi Hospital, Okazaki,
Japan [26], highlighting the potential dissemin-
ation of the genes encoding these enzymes.
Hitherto, Japan has become a major reservoir for
IMP-typeMBLs, which now include IMP-1, IMP-2,
IMP-3, IMP-6, IMP-10 and IMP-11, and these have
spread to a number of strains of Pseudomonas spp.,
Acinetobacter spp. and Enterobacteriaceae.
The belief that IMP-type MBL genes were solely
a distant Japanese problem was dispelled with the
advent of blaIMP-2 in 1997 and blaIMP-5 in 1998 in
Italy and Portugal, respectively [41,42]. The
absence of genetic data concerning these strains
limits our ability to determine whether these IMP-
like genes are actually evidence of dissemination
from Japan or whether they have emerged sepa-
rately in Europe. IMP-type MBLs have now been
found in 12 countries; however, they still appear to
be most proliﬁc in Southeast Asia. The most recent
IMP-likeMBL (IMP-18)was found in aP. aeruginosa
isolate from Las Cruces, North America [43].
The ‘European MBL’ is likely to be that of VIM
rather than IMP, and its global spread (probably
from Europe) is rapid and worrisome. The VIM-
type MBLs are the second dominant group, and
there are currently 13 known derivatives. VIM-1
(Verona imipenemase) was ﬁrst characterised
from a P. aeruginosa strain isolated in 1997 in
Italy [23]. Subsequently, a VIM-1 variant, VIM-2,
was identiﬁed in the southern part of France from
a P. aeruginosa isolate from a blood culture of a
neutropenic patient in 1996 [25]. However, the
‘index’ case of VIM-2 would appear to be a
P. aeruginosa strain isolated from a patient in
Portugal in 1995 [44]. VIM-2 is closely related to
VIM-1 (90% amino-acid identity) (Fig. 1), but
shows appreciably different kinetic properties to
most b-lactams. While there are now 13 variants
of VIM-type MBLS, the dominant genotype is that
of VIM-2, which has, hitherto, been reported from
20 countries in ﬁve continents. The most recent
‘outbreak’ to be reported was from the USA and
involved four patients in an intensive care unit
(ICU); typically, the P. aeruginosa harbouring
VIM-2 was sensitive to aztreonam only [45].
The third type of acquired MBL in Gram-
negative bacilli is SPM-1 (Sao Paulo MBL) [32],
the index strain probably being a bloodstream
isolate from a 4-year-old leukaemic girl who
eventually succumbed to the infection. As is
typical with other MBL-producing organisms,
the isolate was shown to be highly resistant to
all standard anti-Gram-negative anti-infectives
except for colistin [46]. The sequence of SPM-1
possesses moderate identity with that of IMP-1
(35.5%) but is markedly different to that of VIM.
Disturbingly, unsubstantiated reports from Brazil
indicate that approximately 20–45% of P. aerugi-
nosa isolates possess the SPM-1 MBL.
The latest and seemingly rarest MBL is GIM-1,
which was recovered from ﬁve P. aeruginosa
isolates in 2002 from Dusseldorf, Germany (Ger-
Fig. 1. Phylogeny of chromosomally encoded MBLs. Rep-
resented sequences of various MBLs were obtained from
GenBank. MBLs IMP-1, IMP-12 (most divergent from IMP-
1), VIM-1 and VIM-7 (most divergent from VIM-1) were
also added for comparison. Signal peptides were removed
prior to alignment. Sequences were aligned and phylogeny
trees constructed by Clustal W (PAM250 matrix—DNA
Star) using the neighbour-joining method.
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man ImiPenemase) [22]. Like most P. aeruginosa
isolates possessing MBLs, the ﬁve isolates were
only susceptible to polymyxin B. The amino-acid
sequence of GIM-1 displayed most identity with
IMP variants (43.1% with IMP-1), 29% similarity
with VIM-1 and 28% similarity with SPM-1
(Fig. 1). Since 2002, there have been no further
reports of GIM-1-possessing P. aeruginosa isolates.
MECHANISM OF MBL-MEDIATED
HYDROLYSIS
The mechanism of hydrolysis of the amide bond
within the b-lactam ring is different for MBLs
than for serine b-lactamases. MBLs invariably
possess the signature sequence HXHXD, which
facilitates the coordination of zinc ions (usually
two) at the ‘active site’ (Fig. 2). Despite the fact
that MBLs may share less than 25% amino-acid
identity with one another, they all share the
unique abba fold and their active site architec-
tures are virtually superimposable. While not
completely elucidated, the proposed mechanism
of hydrolysis suggests that this active site orients
and polarises the b-lactam bond to facilitate
nucleophilic attack by zinc-bound water ⁄hydrox-
ide [47]. Most MBLs possess a wide plastic groove
and, accordingly, can accommodate most b-lac-
tam substrates, giving rise to their broad
spectrum of activity (Table 1). Moreover, because
MBLs, unlike serine b-lactamases, do not form
highly populated stable covalent intermediates
with their substrate, it would be difﬁcult to arrest
the hydrolytic mechanism with use of a b-lactam-
type compound. Accordingly, MBLs are
impervious to the impeding effects of compounds
such as clavulanic acid and sulbactam [10,48].
Notwithstanding the above, none of the mobile
MBLs are capable of hydrolysing aztreonam
particularly well, indicating that it might be used
as a possible therapeutic inhibitor. However,
animal pneumonia models infected with VIM-2
producing P. aeruginosa could not be eradicated
with aztreonam even when challenged with high
doses [49].
Since the introduction of amoxycillin–clavula-
nate in the 1980s, the potentiation between a
b-lactam and a b-lactamase inhibitor could be
theoretically used to treat any infection with
b-lactamase-producing bacteria. However, inhib-
iting all clinically relevant MBLs will be a colossal
undertaking and there are many toxicity issues
that may arise, due to human binuclear enzymes
possessing an almost identical active site, e.g.,
glyoxalase II [50]. Moreover, many studies explor-
ing the potentiation by experimental inhibitors
have not used whole-cell assays. This is likely to
be a major obstacle with organisms such as
P. aeruginosa and Acinetobacter spp.
Fig. 2. Direct comparison of Bacillus cereus BCII MBL (left)
with IMP-1 (right) [75,76]. While these enzymes possess
little homology (< 25% similarity), their structures possess
the unique abba fold and are virtually superimposable.
The grey spheres represent zinc ions, which would
normally coordinate water ⁄hydroxide molecules necessary
for the hydrolysis of the b-lactam amide bond.
Table 1. Relative hydrolytic efﬁciencies of transferable
MBLs
aIMP-1 bVIM-1 cVIM-2 dSPM-1 eGIM-1
Penicilllin G 196 217 453 326 54
Ampicillin 1116 263 92 299 31
Carbenicillin – 5606 93 43 21
Azlocillin – 17020 101 101 –
Piperacillin – 3838 238 317 51
Ticarcillin 0.5 2728 261 – 18
Nitroceﬁn 146 1768 809 2 58
Cephalothin 115 40986 403 158 147
Cefuroxime 18 12777 8.4 136 61
Cefoxitin 43 232 16 30 37
Ceftazidime 17 505 3 81 161
Cefotaxime 3.5 3202 76 57 12
Cefepime 18 14090 13 61 47
Imipenem 100 100 100 100 100
Meropenem 128 192 6 83 25
Moxalactam 2.3 400 104 30 19
aLaraki et al. 1999 (76); bFrancheschini et al. 2000. (44), cDocquier et al. 2003 (40),
dMurphy et al. 2003 (98), eCastanheira et al. 2004. (29)
Hydrolytic rates were determined by the Michaelis-Menton steady-state equation
where V ¼ Kcat [E][S]/Km + [S]. [S] was kept at a 150 lM for all b-lactam
substrates and imipenem was standardised at a relative rate of 100.
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THE DISSEMINATION OF MBLS
Within the realm of resistant genes that bacteria
procure and evince, some genotypes appear to
dominate while others make only a ﬂeeting
appearance. The reasons for this may be multiple
but are likely to involve the genetic elements on
which the genes are carried, as well as the
promiscuity and subsequent ‘ﬁtness’ of the recipi-
ent bacteria. Moreover, there is little doubt that
the increase in human travel has further enhanced
the spread of resistance, as exempliﬁed by the
ﬁrst Scandinavian P. aeruginosa (blaVIM-4) isolate,
which was introduced into Sweden via a Greek
patient [51]. Notwithstanding stringent infection
control policies, the MBL gene pool in some
countries may already be ﬁrmly established. For
example, the ﬁrst P. aeruginosa isolate possessing
blaSPM-1 was isolated in 1997 and now appears to
contribute approximately 25–40% of the pseudo-
monal population, severely limiting antimicrobial
regimens in some hospitals. This may also be the
case with the P. aeruginosa carrying VIM-2 that
possibly arose from a patient residing in Portugal
in 1995 [44]. Since 1995, blaVIM-2-positive P. aeru-
ginosa has appeared in France, Italy, Greece,
Spain, Poland, Croatia, Germany, Belgium and
Russia, and has asserted itself as the dominant
European MBL [31,52–56]. It has also been found
in Venezuela, Chile, Argentina, Korea, Japan,
Taiwan, Saudi Arabia and, most recently, from
an outbreak in the USA [57–61]. It is quite
probable that the gene pool is more extensive
than that which we can detect and is either in a
quiescent state or is not being detected, or both, as
demonstrated by the Taiwanese study, in which
140 multiresistant K. pneumoniae isolates were
examined for IMP- and VIM-type genes with
reference to hybridisation studies, in which 40
were positive for IMP, yet only 5 ⁄ 40 were carb-
apenem-resistant [62]. Such studies provide an
excellent insight into the silent gene pool which is
undetected by standard microbiological testing
regimens.
It is perhaps not coincidental that IMP, VIM,
SPM and GIM ﬁrst appeared in Pseudomonas
(usually P. aeruginosa) before appearing in Acine-
tobacter spp. and Enterobacteriaceae. The reason
for this is not clear but is likely to involve the
universality, or lack thereof, of the genetic appar-
atus carrying the MBL genes, i.e., broad host
range plasmids. Over a period of time it is highly
likely that these genes will ﬁnd mobile elements
that can be accommodated in most Gram-negat-
ive bacteria. Unfortunately, little information con-
cerning the plasmids that carry MBL genes is
available and no ﬁtness studies have been under-
taken using native plasmids carrying MBL genes,
which may provide a benchmark as to how
successful they will be in spreading to Enterobac-
teriaceae. Moreover, no b-lactam efﬁcacy animal
studies have been undertaken to examine eradi-
cation of MBL-positive Enterobacteriaceae, the
data from which would provide a prediction of
their clinical importance and an indication of
whether altered dosing regimens may prove
efﬁcacious.
THERAPEUTIC REGIMES FOR
PAN-RESISTANT GRAM-NEGATIVE
BACTERIA
The dissemination of MBL genes is thought to
be driven by the regional consumption of
extended-spectrum cephalosporins or carbapen-
ems [63,64], and therefore care must be taken
that these drugs are not used unnecessarily.
Furthermore, given that MBL-possessing bac-
teria often appear sensitive or intermediately
sensitive to carbapenems, MIC testing is advis-
able, as disk diffusion is unlikely to detect
borderline cases.
The MBL producers that are most clinically
signiﬁcant are primarily those in which the gene
encoding the enzyme is transferable. These
MBL-positive strains are usually resistant to
b-lactams, aminoglycosides and quinolones,
and, as has recently been shown, inappropriate
therapy can be associated with adverse out-
come, particularly in high-risk patient groups
[65]. Hitherto, there has been no suitable ther-
apy for treating these infections. However, in a
recent clinical study by Lee et al., the therapy
and clinical outcome of six patients infected
with MBL-positive Gram-negative bacilli were
tracked, and in each case the infection was
eradicated. In most cases, a b-lactam was used
in combination with one or more other antibi-
otics; however, no detailed information was
provided concerning the organism’s susceptibil-
ity to the other compounds or what resistance
genes were associated with the MBL genes [66].
At the present time, no MBL inhibitors are
available for treating patients, and there are not
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likely to be any in the foreseeable future.
Co-resistance with other compounds, such as
aminoglycosides, is likely to further diminish
other therapeutic options [48]. The only thera-
peutic alternative may be the administration of
polymyxins, which have been shown recently to
be efﬁcient in treating multidrug-resistant Gram-
negative bacilli [67]. It has been claimed recently
that polymyxins are not as toxic as previously
thought; however, it would be prudent to consi-
der polymyxins only as part of combination
therapy [68,69].
Clearly, there is a need to produce new and
efﬁcacious compounds to combat MBL-positive
Gram-negative bacteria. However, there appear to
be very few new compounds demonstrating
potent activity against P. aeruginosa and Acinetob-
acter spp., even without an MBL [70]. The reasons
for this are multifactorial, but largely centre on
the lack of net return proﬁts that companies will
receive once an anti-pseudomonal drug has been
developed [38,71]. Such a compound may require
the better part of $800 million to develop and will
only be used in highly specialised circumstances,
even in life-threatening situations. Sadly, net
returns to large pharmaceutical companies are
far higher for lifestyle drugs than for those
mitigating serious infections, and it is these that
are seen as commercially attractive. This crisis
heralds the desperate need for governmental
support in drug research and development pro-
grammes if longevity is to be guaranteed [71].
Non-fermenting Gram-negative bacteria are par-
ticularly difﬁcult to eradicate, as their outer-
membrane provides a formidable barrier that is
difﬁcult to breach. Accordingly, attention appears
to be increasingly turning to small proteins as
anti-infectives, some of which are highly cidal and
may not pose the toxic risks ﬁrst feared [72].
Given the lack of new compounds that are likely
to be efﬁcacious against pan-resistant Gram-neg-
ative bacteria, news reports heralding the ‘end of
the antibiotic era by 2015’ appear to be increas-
ingly less dubious.
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